This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Testosterone deficiency (TD) therapy if prostate cancer

Authoring team

Testosterone therapy and prostate cancer

Testosterone therapy can be offered to men with symptomatic TD and treated localised low-risk prostate cancer (Gleason score <8, stages 1-2, preoperative prostate specific antigen (PSA) <10ng/mL), as long as it is not started before 1 year of follow-up and they have no evidence of active disease (based on measured PSA level, DRE result and absence of metastases).

Reference:

  1. Jayasena CN, Anderson RA, Llahana S, et al. Society for Endocrinology guidelines for testosterone replacement therapy in male hypogonadism. Clin Endocrinol (Oxf). 2022 Feb;96(2):200-19.
  2. Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018 May 1;103(5):1715-44.

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.